Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles
- Registration Number
- NCT01007851
- Lead Sponsor
- V.K.V. American Hospital, Istanbul
- Brief Summary
GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI.
- Embryo transfer performed on day 3
Read More
Exclusion Criteria
- Participation in another trial that was being conducted in our unit at the same time.
- Preimplantation genetic screening cycles.
- Day 5 embryo transfers.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description GnRH agonist triptorelin acetate - Saline NaCl %0.9 -
- Primary Outcome Measures
Name Time Method Ongoing pregnancy beyond 20th gestational week
- Secondary Outcome Measures
Name Time Method clinical pregnancy rate Embryo implantation rate
Trial Locations
- Locations (1)
American Hospital
🇹🇷Istanbul, Turkey